3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
0
Active Trials
4
Rare Diseases
across 5 areas
0
News (30d)
Quiet
Xspray Pharma AB is a company with 3 orphan drug designations across 4 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| adult acute lymphoblastic leukemia | dasatinib | Des.TrialAppr. |
| chronic myelogenous leukemia, BCR-ABL1 positive | dasatinibnilotinib oral formulation | Des.TrialAppr. |
| juvenile myelomonocytic leukemia | dasatinib | Des.TrialAppr. |
| leukemia, myeloid, accelerated-phase | dasatinib | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
1
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio